VICTORIA, Feb. 20, 2020 /CNW/ - ImmunoPrecise
Antibodies Ltd (the "Company"), a provider of best-in-class
therapeutic antibody discovery capabilities for the global
industry, announces its commitment to the development of
innovative vaccines against the new coronavirus originating in
Wuhan, China (SARS-CoV-2) as well
as coronavirus-neutralizing antibodies, addressing both
prophylactic and therapeutic measures to fight the virus and its
associated disease, COVID-19.
![ImmunoPrecise (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1093294/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_Launches_Coronavirus.jpg)
IPA's Rapid Research and Development (RR&D) Team is
leveraging its unique ability to address global, pandemic crises in
an abbreviated timeframe. To date, the virus has caused
approximately 1,875 deaths and over 74,000 known infections and is
rapidly expanding worldwide. ImmunoPrecise has designated Dr. Ilse
Roodink, the chairwoman of IPA's subsidiary Talem Therapeutic's
scientific committee, as the Coronavirus Global Project Leader.
Under her supervision, the Company has embarked on a global
response and properly designed campaign. The sophisticated
infrastructure of IPA significantly contributed to a quick, but
sensible, response initiated by the design and production of
relevant SARS-CoV-2 target antigens to facilitate the upcoming
identification of prophylactic and therapeutic compounds using
IPA's proprietary discovery platforms (including B Cell
Select™ and DeepDisplay™) and Talem's access
to the leading transgenic animal platform OmniAb® for
direct generation of human antibodies.
"We believe that ImmunoPrecise will make an impressive
contribution to the global fight against SARS-CoV-2," stated Dr.
Jennifer Bath, President and CEO of
ImmunoPrecise Antibodies. "With the aid of iterative advancements
rapidly compiling from across the globe, including data such as the
February 19th release of
the prefusion form of the new coronavirus spike glycoprotein,
research teams are advancing the collective effort toward the
development of efficacious vaccines, therapeutic antibodies, and
diagnostics. We grow more determined each day about contributing to
this endeavor, as we monitor the rapid, global spread of
SARS-CoV-2."
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell Select™ progressive single-cell
interrogation technology and the DeepDisplay™ custom,
OmniAb®-based phage libraries, as well as the
Abthena™ bispecific program. IPA is focused on the next
generation of antibody discovery, to deliver the most
therapeutically relevant antibodies, in a shorter period of time,
with the highest probability of succeeding to clinical trials.
ImmunoPrecise's discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria,
British Columbia (IPA Canada). The Company operates globally
to offer a continuum of superior antibody services, transforming
the face of therapeutic discovery, by decreasing turnaround time
and risk, and promoting clinical success.
There is no assurance that the Company will be successful in the
development of a vaccine and/or therapeutic against the new
coronavirus. In particular, the development of a vaccine
and/or therapeutic requires significant capital, which will require
additional financing by the Company, successful clinical trials and
extensive regulatory approvals.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended October 31, 2019 which can be accessed at
www.sedar.com. The "forward-looking statements" contained
herein speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-launches-coronavirus-vaccine-and-therapeutic-antibody-program-301008684.html
SOURCE ImmunoPrecise Antibodies Ltd.